艾昆纬-多发性骨髓瘤的微小残留病:加速批准的关键监管里程碑(英)-2026.pdfVIP

  • 2
  • 0
  • 约4.57万字
  • 约 13页
  • 2026-05-21 发布于内蒙古
  • 举报

艾昆纬-多发性骨髓瘤的微小残留病:加速批准的关键监管里程碑(英)-2026.pdf

WhitePaper

MinimalResidualDiseaseinMultiple

Myeloma:APivotalRegulatoryMilestone

forAcceleratedApproval

SARIHEITNERENSCHEDE,MD,HeadofHematology,SeniorMedicalStrategyLead,

Hematology-OncologyCenterofExcellence

MEGANMCCAUSLAND,Director,FlowCytometry,IQVIALaboratories

FRANKLINSEDARAT,MD,GlobalHead,Hematopathology,IQVIALaboratories

BRADLEYSMITH,PhD,VicePresidentTherapeuticStrategy,IQVIADrugDevelopmentand

RegulatoryStrategy

Tableofcontents

Introduction1

文档评论(0)

1亿VIP精品文档

相关文档